Catalyst
Slingshot members are tracking this event:
Boston Scientific Announces U.S. FDA Approval of Navigation-Enabled Ablation Catheters
Do you think this event is important to the companies below? How will it affect their stock price?
Related Companies | Importance
|
Impact on Stocks
|
||||
---|---|---|---|---|---|---|
BSX | Community voting in process |
Additional Information
"By combining these new magnetic navigation-enabled catheters with our high-density, high-resolution Rhythmia Mapping System, we can create enhanced maps that help diagnose arrhythmias and improve guidance during cardiac ablation procedures," said Kenneth Stein, M.D., chief medical officer, Rhythm Management, Boston Scientific. "With these approvals, we continue the expansion of our electrophysiology product offerings, further demonstrating our commitment to help electrophysiologists provide the highest quality of care for their patients."
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 03, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Ablation Catheters, Type I Atrial Flutter, Magnetically-tracked Catheters